中文

← All funding rounds

Multiply Labs

United StatesAutonomous labsSan Francisco, United StatesFounded 2016Private

Website · multiplylabs.com ↗

Builds robotic clusters that run the manual steps of making cell and gene therapies and other biologics, working with the drugmaker's existing equipment; the drugmakers own and operate the robots.

Disclosed total$75M
Rounds on record1
Latest round$75MSeries B · 2026-10-06
Last stated valuationNone stated
Investors named10
Research on record1highest level 4 · Tested in the physical world

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date$75MEvidencelevel of each research entry12345
Closed roundResearch entry, at its level

Latest round, Series B, 2026-10-06: the record then held 1 research entry, highest level 4. The first research entry is dated 2026-08-04; the highest level so far is 4 (Tested in the physical world).

Rounds and research, on one timeline

  1. 2026-10-06Series B
    Round

    $75M

    For: expanding manufacturing capacity, speeding up product development and growing its engineering, regulatory and commercial teams

    Manufacturing and scale-upHiring

    The report says Patrick Soon-Shiong and NantWorks led, and that total raised passes $100M; the company's own release was not found.

    Lead · NantWorksAstraZenecaLingottoTeradyneStrange VenturesExisting investor · Casdin CapitalExisting investor · Lux CapitalExisting investor · Fifty YearsExisting investor · Ora GlobalExisting investor · Founders Fund

    On the deal: Patrick Soon-Shiong (Founder of NantWorks; led the round with it, NantWorks)

    By this date the record held 1 research entry, highest level 4

    Reported by The AI Insider · theaiinsider.tech ↗On the timeline →

  2. 2026-08-04
    Research

    Level 4 · Tested in the physical world

    A Multiply Labs robot cluster matches skilled operators on cell-therapy steps, with a lower cell count at low concentration

    Autologous cell therapies are still made by hand, one patient at a time, and that cost is why they reach few people. What decides whether a robot can take over a validated process is whether the same instrument gives the same numbers, and here it mostly did. Mostly: at low concentration the robot counted significantly fewer cells than the operators (5.63 against 5.91 x 10^5 per mL), the CytoSinct needed its wash and elution lengthened, bag-to-bag transfer was robot-only, and the cells' phenotype and function were out of scope. The authors call it an R&D prototype.

    Timeline entry →doi.org ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

Its investors also backed

Other companies on this page whose rounds name the same investor.